EUVIMEDEUVIMED entdecken
Crossref

Discovery and Optimization of a WRN Helicase Inhibitor Series through Structure-Guided Drug Design from a Covalent Fragment Binding Insight

Momar Toure iD, Xin Cindy Yan, Yonghong Bai, Brian A Sosa-Alvarado, Cen Gao, Theresa Baker, Erin Brophy, John R Butler iD, Yuchen Yuan, Michael H Reutershan iD, Anthony Tubbs, Laurie Schenkel und 6 weitere

Journal of Medicinal Chemistry · 13.08.2026 · 69 (15) · 18162-18181

DOI: 10.1021/acs.jmedchem.6c00443 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 04.08.2026. Verfasst von Momar Toure und 17 weiteren Autor:innen. Beteiligte Einrichtung: MOMA Therapeutics, Cambridge, Massachusetts02142-1213, United States. Hauptthemen laut MEDLINE: Drug Design, Werner Syndrome Helicase, Enzyme Inhibitors, Drug Discovery. Die Arbeit nennt 45 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

WRN helicase activity inhibition has emerged as a promising therapeutic approach for targeting cancer cells with specific DNA repair deficiencies, especially those with microsatellite instability (MSI). Herein, we report a novel covalent WRN helicase inhibitor series discovered and optimized by leveraging insights from a covalent fragment investigation. Initial structure-based design led to potency-optimized compounds from this series that exhibited unbound cellular potency in the nanomolar range in both p21 induction and HCT116 CTG viability assays, albeit with high intrinsic warhead reactivity. Further refinement of the ADME properties by modulating the warhead reactivity yielded lead WC-2 with excellent cellular potency, low reactivity toward GSH, excellent plasma and blood stabilities, good oral bioavailability, and long in vivo half-lives in rat (T1/2 = 7.2 h; F = 62%) and dog (T1/2 = 18.9 h). WC-2 has the potential as a next-generation, low-dose WRN helicase clinical candidate for treating patients with MSI-classified tumors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug DesignWerner Syndrome HelicaseEnzyme InhibitorsDrug DiscoveryHumansAnimalsRatsStructure-Activity RelationshipDogsHCT116 CellsAntineoplastic AgentsModels, Molecular

Substanzen

Werner Syndrome HelicaseEnzyme InhibitorsWRN protein, humanAntineoplastic Agents

Autor:innen und Institutionen

  • MOMA Therapeutics, Cambridge, Massachusetts02142-1213, United States.

ORCID-Profile: Momar Toure, John R Butler, Michael H Reutershan

Zitieren

APA

Toure, M., Yan, X. C., Bai, Y., Sosa-Alvarado, B. A., Gao, C., Baker, T., Brophy, E., Butler, J. R., Yuan, Y., Reutershan, M. H., Tubbs, A., Schenkel, L., Bottoni, G., Evans, E., Hammerman, P., Drew, A., Guzi, T., & McGowan, M. A. (2026). Discovery and Optimization of a WRN Helicase Inhibitor Series through Structure-Guided Drug Design from a Covalent Fragment Binding Insight. Journal of Medicinal Chemistry, 69(15), 18162-18181. https://doi.org/10.1021/acs.jmedchem.6c00443

Vancouver

Toure M, Yan XC, Bai Y, Sosa-Alvarado BA, Gao C, Baker T, et al. Discovery and Optimization of a WRN Helicase Inhibitor Series through Structure-Guided Drug Design from a Covalent Fragment Binding Insight. Journal of Medicinal Chemistry. 2026;69(15):18162-18181. doi:10.1021/acs.jmedchem.6c00443

BibTeX
@article{Toure2026,
  author = {Toure, Momar and Yan, Xin Cindy and Bai, Yonghong and Sosa-Alvarado, Brian A and Gao, Cen and Baker, Theresa and Brophy, Erin and Butler, John R and Yuan, Yuchen and Reutershan, Michael H and Tubbs, Anthony and Schenkel, Laurie and Bottoni, Giulia and Evans, Erica and Hammerman, Peter and Drew, Allison and Guzi, Timothy and McGowan, Meredeth A},
  title = {Discovery and Optimization of a WRN Helicase Inhibitor Series through Structure-Guided Drug Design from a Covalent Fragment Binding Insight},
  journal = {Journal of Medicinal Chemistry},
  year = {2026},
  volume = {69},
  number = {15},
  pages = {18162--18181},
  doi = {10.1021/acs.jmedchem.6c00443}
}
Kostenlos starten →